Drug Profile
MSI 1566
Latest Information Update: 14 Aug 2007
Price :
$50
*
At a glance
- Originator Genaera Corporation
- Class Antimalarials; Steroids
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 19 Jun 2001 No-Development-Reported for Malaria in USA (Unknown route)
- 07 Jul 1998 Preclinical development for Malaria in USA (Unknown route)